163 related articles for article (PubMed ID: 38666760)
1. Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Sanchez C; Poterico JA; Tarazona-Santos E; Guio H
Pharmacol Res Perspect; 2024 Jun; 12(3):e1179. PubMed ID: 38666760
[TBL] [Abstract][Full Text] [Related]
2. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
[TBL] [Abstract][Full Text] [Related]
3.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Vasquez-Dominguez A; Toledo-Nauto A; Capristano S; Sanchez C; Tarazona-Santos E; Ugarte-Gil C; Guio H
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232322
[TBL] [Abstract][Full Text] [Related]
4. Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.
Levano KS; Jaramillo-Valverde L; Tarazona DD; Sanchez C; Capristano S; Vásquez-Loarte T; Solari L; Mendoza-Ticona A; Soto A; Rojas C; Zegarra-Chapoñan R; Guio H
Mol Genet Genomic Med; 2021 Oct; 9(10):e1764. PubMed ID: 34510815
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
6. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
[TBL] [Abstract][Full Text] [Related]
7. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
[TBL] [Abstract][Full Text] [Related]
8. Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study.
Pourmohamadi N; Pour Abdollah Toutkaboni M; Hayati Roodbari N; Tabarsi P; Baniasadi S
Iran J Med Sci; 2023 Sep; 48(5):474-483. PubMed ID: 37786472
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
10. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
[TBL] [Abstract][Full Text] [Related]
11. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
12. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
13. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
[TBL] [Abstract][Full Text] [Related]
14. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Chang SC; Chiang CH; Chang FY; Lee SD
Hepatology; 2003 Apr; 37(4):924-30. PubMed ID: 12668988
[TBL] [Abstract][Full Text] [Related]
16. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
[TBL] [Abstract][Full Text] [Related]
17. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
18. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
20. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]